Wegovy pill switch study reports further weight loss after injections

Adults who switched from weekly semaglutide or tirzepatide injections to the daily Wegovy pill lost a further 4.1% of body weight on average over three months, according to a real world analysis presented by Novo Nordisk. The study, called OCTANE, used records from 194 people on a US telehealth platform and had no comparison group. It was presented as a late breaking abstract at the European Association for the Study of Diabetes meeting in Milan on September 30, 2026. It shows what happened after a switch, not whether the pill works as well as the shots.

What the OCTANE analysis looked at

OCTANE was a retrospective cohort analysis of de-identified data from a direct to consumer telehealth service, combining health records, patient reported data and pharmacy records, according to the Novo Nordisk release. It drew a random sample of adults with obesity, or with overweight plus at least one weight related condition such as high blood pressure, abnormal blood lipids, sleep apnea or heart disease. People with diabetes or earlier bariatric surgery were excluded. All 194 had moved from injectable semaglutide or tirzepatide to oral semaglutide between early January and early February 2026. On average, 36.8 days passed between the last injectable prescription and the first pill.

At the switch, participants weighed 100.5 kilograms on average and had an average body mass index of 34.5. They had to keep taking the pill without a gap longer than 30 days to stay in the analysis. That rule matters, because it leaves out anyone who stopped early for side effects, cost or a poor response. The release did not say how much weight participants had lost on the injections before switching, or how long they had used them. Without that history, it is hard to tell whether the pill extended an ongoing loss or recovered ground lost during the gap between products. Louis J. Aronne of Weill Cornell Medicine is one of the co-authors.

Results at three months

Three months after the switch, average weight had fallen by 4.1%, or 4.0 kilograms, from the level at the switch, Novo Nordisk said, a change it reported as statistically significant. Of the 194 participants, 40.7% lost at least 5% of their body weight in that time. The share with a body mass index of 30 or more, the usual threshold for obesity, fell from 87.1% to 65.5%. Among participants with available answers, 82.4% reported at least one improvement, most often better fitting clothes and healthier eating. The release did not report side effects or discontinuation rates from the analysis, so the tolerability of the switch cannot be judged from these data.

Of the 194 participants, 40.7% lost at least 5% of their body weight in that time.

Novo listed the limits of the work itself. Routine telehealth records vary in timing and completeness, self reported data can be biased, the persistence rule may have selected people who were doing well, and the results may not apply to other settings. Real world studies show associations and cannot prove cause, the company noted. Aronne said that "a switch to oral semaglutide may be a viable path for the right patient." That is a cautious framing, and the data support no more than that. Readers can use the same checks this site suggests for any weight loss trial headline before reading too much into a single figure.

How the switch compares with a randomised pill trial

The stronger evidence on moving from shots to a pill comes from a different drug. In the ATTAIN-MAINTAIN trial, Lilly randomised 376 people in the United States who had used tirzepatide or semaglutide injections for 72 weeks to its daily orforglipron pill or to placebo for a year. Those on orforglipron kept 75% to 79% of their earlier weight loss, against 38% to 49% on placebo, Hospital Pharmacy Europe reported; the results were published in Nature Medicine. Orforglipron is a small molecule rather than a peptide, a difference this site covered when the non peptide weight loss pill posted its first obesity results.

The two studies answer different questions. ATTAIN-MAINTAIN asked whether a pill can hold weight loss compared with stopping treatment, and it used randomisation to answer that. OCTANE asked what happened to weight in people who chose to switch and kept going, and it had no group that stayed on injections or stopped. Neither study shows that the Wegovy pill and the injections are interchangeable for an individual patient. Oral semaglutide must be absorbed through the stomach, which is the engineering challenge described when the first tablet for weight management was approved, and its dose is not a simple conversion from the weekly shot.

What the data mean for patients and the market

For patients, the practical message is narrow. Some people who move from a weekly injection to the Wegovy pill may keep losing weight in the following months, at least when they stay on it. Whether to switch, and to which strength, is a decision for a prescriber who knows the person's history, since the injectable and oral products have different labels and dosing schedules. Both carry the same class warnings, including a boxed warning about possible thyroid tumours, and the common side effects are stomach related. Anyone considering a change should not stop an injection and start a pill from another source without medical advice.

For the market, the study is part of Novo Nordisk's push to establish its tablet. The company said the pill has launched in the United States, the United Arab Emirates, the United Kingdom and Germany, with more markets planned in the coming quarters. Martin Holst Lange, Novo's chief scientific officer, said: "We innovate to meet people with obesity where they are." Real world switch data like OCTANE help a company argue for a product, which is one reason independent and randomised studies matter. A prospective trial comparing people who switch with people who stay on injections would give a clearer answer than records drawn from routine care.

Conclusion

The OCTANE analysis suggests that adults who moved from weekly injections to the daily Wegovy pill, and stayed on it, lost another 4.1% of weight on average over three months. The study is small, retrospective and company presented, it has no control group, and it excludes people who stopped. A randomised trial with another pill showed that switching can hold most earlier weight loss. A controlled study of the Wegovy pill as a step down from injections would settle what this analysis cannot.